Filing Flows › Metagenomi Therapeutics (MGX) › Q1 2026 › vs Q4 2025
Metagenomi Therapeutics (MGX) Q1 2026 vs Q4 2025 (quarter over quarter)
Metagenomi Therapeutics's revenue fell $2.7M (-68%) from $3.9M in Q4 2025 to $1.2M in Q1 2026.
Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year), net loss $23.1M, operating cash flow −$21.2M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.2M | $3.9M | −$2.7M | -68% |
| Other income, net | $1.5M | $1.9M | −$335K | -18% |
| Net loss | $23.1M | $22.5M | $531K | +2% |
| Costs & expenses | $25.8M | $28.3M | −$2.5M | -9% |
| Operating costs | $25.8M | $28.3M | −$2.4M | -9% |
| Income tax | $10K | $34K | −$24K | -71% |
| Research & development | $19.3M | $21.5M | −$2.2M | -10% |
| General & admin | $6.5M | $6.8M | −$242K | -4% |
| Operating cash sources | $25.0M | $27.5M | −$2.5M | -9% |
| Depreciation | $1.3M | $1.3M | −$25K | -2% |
| Share-based compensation | $2.6M | $2.7M | −$142K | -5% |
| Cash used in operations | $21.2M | $23.5M | −$2.4M | -10% |
| Net loss absorbed | $23.1M | $22.5M | $531K | +2% |
| Working capital & other | $1.9M | $5.0M | −$3.1M | -61% |
Questions
How much did Metagenomi Therapeutics's revenue grow quarter over quarter in Q1 2026?
Metagenomi Therapeutics's revenue fell $2.7M (-68%) from $3.9M in Q4 2025 to $1.2M in Q1 2026.